で公開中です！詳しく見る

Journey Medical

DERM

時価総額 $1.4億

4.96 USD

-0.17

3.31%

終値時点更新済み 10月16日 16:00 EDT

1日

-3.31%

5日間

-22.5%

1か月

-31.96%

3か月

-30.24%

6か月

-4.06%

年初来

-33.42%

1年

-32.97%

5年間

-47.79%

10年間

-47.79%

概要： Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

従業員数： 58

ヘルスケア医薬品メーカー（スペシャリティ・ジェネリック）

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 40%

ニュートラル 60%

ネガティブ 0%

ポジティブ

Journey Medical: A Small Pharma With A Large Growth Opportunity

Journey Medical (DERM) is rated Buy, driven by Emrosi's rapid prescription growth and expanding payer coverage. DERM leverages existing infrastructure for Emrosi, achieving high gross margins and operating leverage, pushing toward sustainable profitability. Conservative growth assumptions and a 4x EV/Sales multiple yield a $15 target price, implying 109% upside over three years.

Journey Medical: A Small Pharma With A Large Growth Opportunity

ニュートラル

Journey Medical Corporation to Participate in September 2026 Investor Conferences

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.

Journey Medical Corporation to Participate in September 2026 Investor Conferences

ポジティブ

Zacks Investment Research

ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?

Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.

ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?

ポジティブ

Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction

Journey Medical demonstrates strong Emrosi prescription growth, rebounding from Q1 lows with Q2 revenues up 23% to $18.5M and positive EBITDA. DERM's Emrosi franchise is gaining traction, with prescribers rising over 40% quarter-over-quarter and formulary coverage improving from 34% to 38%. Cost discipline is evident as SG&A declined and operating expenses rose less than 1%, while Emrosi's ASP and market penetration are expected to improve further.

Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction

ニュートラル

Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript

Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript

Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript

ニュートラル

Zacks Investment Research

Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings

The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings

ポジティブ

Journey Medical Q2 Earnings Call Highlights

Journey Medical NASDAQ: DERM reported higher second-quarter revenue and a sharply narrower net loss as sales of its rosacea treatment EMROSI continued to grow, supported by rising prescription volume, broader prescriber adoption and improving payer reimbursement.

Journey Medical Q2 Earnings Call Highlights

ニュートラル

Zacks Investment Research

Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.

Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

ニュートラル

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

ニュートラル

Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026.

Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています